-
公开(公告)号：US20190070248A1
公开(公告)日：2019-03-07
申请号：US15741902
申请日：2015-07-14
Applicant: Biontech AG , Tron-Translationale Onkologie An Der Johannes Gutebert-Universital Mainz GGMBH , JPT Peptides Technologies GMBH
Inventor： Ugur Sahin , Laura Marie Kring , Markus Fiedler , Matin Daneschdar , Hans-Ulrich Schmoldt , Ulf Reimer , Karsten Schnatbaum
Abstract: The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3ε). These molecules compete with CD3ε for binding to a CD3ε binding domain. e.g. a CD3ε binding domain of an antibody, and are capable of detecting antibodies against CD3ε. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3ε antibody purification and the detection of anti-CD3ε antibodies in biological samples.
-
Patent Agency Ranking
公开(公告)号：US10858415B2
公开(公告)日：2020-12-08
申请号：US15113981
申请日：2014-01-29
Applicant: BioNTech AG , TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg—Universitat Mainz gemeinnutzige GmbH , Universitatsmedizin der Johannes Gutenberg—Universitat Mainz , JPT Peptide Technologies GmbH
Inventor： Ugur Sahin , Matin Daneschdar , Hans-Ulrich Schmoldt , Laura-Marie Kring (née Plum) , Markus Fiedler , Ulf Reimer , Karsten Schnatbaum
IPC: A61K38/08 , A61K38/12 , C07K5/00 , A61K38/04 , C07K7/00 , C07K16/00 , C07K17/00 , C07K14/705 , C07K7/64 , A61K39/00 , G01N33/53 , G01N33/574
Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
-
公开(公告)号：US20200031898A1
公开(公告)日：2020-01-30
申请号：US16595440
申请日：2019-10-07
Applicant: BioNTech AG , TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz , Universitatsmedizin der Johannes Gutenberg-Universitat Mainz , JPT Peptide Technologies GmbH
Inventor： Ugur Sahin , Matin Daneschdar , Hans-Ulrich Schmoldt , Laura-Marie Kring (née Plum) , Markus Fiedler , Ulf Reimer , Karsten Schnatbaum
IPC: C07K14/705 , G01N33/53 , A61K39/00 , G01N33/574
Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
-
公开(公告)号：US10370433B2
公开(公告)日：2019-08-06
申请号：US15552215
申请日：2016-03-15
Applicant: BIONTECH AG
Inventor： Ugur Sahin , Joycelyn Wüstehube-Lausch , Markus Fiedler , Matin Daneschdar , Hans-Ulrich Schmoldt
Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
-
公开(公告)号：US20180037632A1
公开(公告)日：2018-02-08
申请号：US15552215
申请日：2016-03-15
Applicant: BIONTECH AG
Inventor： Ugur Sahin , Joycelyn Wüstehube-Lausch , Markus Fiedler , Matin Daneschdar , Hans-Ulrich Schmoldt
IPC: C07K14/81
CPC classification number: C07K14/811 , C12Y304/21026
Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
-
公开(公告)号：US20160347815A1
公开(公告)日：2016-12-01
申请号：US15113981
申请日：2014-01-29
Applicant: BIONTECH AG , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERS , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG- UNIVERSITÄT MAINZ , JPT PEPTIDE TECHNOLOGIES GMBH
Inventor： Ugur Sahin , Matin Daneschdar , Hans-Ulrich Schmoldt , Laura Marie Plum , Markus Fiedler , Ulf Reimer , Karsten Schnatbaum
IPC: C07K14/705 , G01N33/53 , A61K39/00 , G01N33/574
CPC classification number: C07K14/705 , A61K39/0005 , G01N33/5308 , G01N33/57492 , G01N2333/705 , G01N2500/02 , G01N2500/04
Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
Abstract translation: 本发明提供模拟整合的跨膜蛋白克劳丁18.2（CLDN18.2）的抗原决定簇的分子。 这些分子与CLDN18.2竞争结合CLDN18.2结合结构域，例如。 抗体的CLDN18.2结合结构域，并且能够检测针对CLDN18.2的抗体。 本发明的模拟表位可用于产生或抑制动物和优选人类的免疫应答。 此外，它们可以用于检测在生物样品中包含CLDN18.2结合结构域的试剂以及用于包含CLDN18.2结合结构域的纯化剂的目的。
-
-
-
-
-
Search Results
6
records
(took 0.02 seconds)
